Axitinib ophthalmic - Clearside Biomedical

Drug Profile

Axitinib ophthalmic - Clearside Biomedical

Alternative Names: CLS 1002; CLS011A

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clearside Biomedical
  • Class Antineoplastics; Eye disorder therapies; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 14 Mar 2017 Axitinib ophthalmic - Clearside Biomedical is available for licensing as of 14 Mar 2017. www.clearsidebio.com
  • 27 Feb 2017 Clearside Biomedical does not intend to submit an IND to US FDA
  • 05 Jan 2017 Clearside receives notice of allowance for suprachoroidal space drug delivery to treat Eye disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top